Oxford Biomedica Regulatory News (OXB)

Oxford BioMedica Director Declaration

Oxford, UK - 22 May 2014: Oxford BioMedica plc (LSE: OXB), ("the Company") the leading gene based biopharmaceutical company, today announces that, in accordance with LR 9.6.14 R, it has been informed that John Dawson, Chief Executive Officer of the Company, has been appointed Non-Executive Director of PAION AG.

-Ends-

Notes for editors

About Oxford BioMedica®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad range of partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.